February 23, 2018 09:52 AM EST
News Briefing

FDA of­fers quick re­view for Shire's prospec­tive block­buster lanadelum­ab; Big Phar­ma loves big buy­backs

Brittany Meiling

→ The FDA is help­ing Shire $SH­PG hus­tle along its ap­pli­ca­tion for lanadelum­ab, which the big biotech be­lieves can peak out at $2 bil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times